Allogene Therapeutics, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 152
Rang # Quantité totale PI 8 631
Note d'activité PI 3/5.0    149
Rang # Activité PI 4 609
Symbole boursier ALLO (nasdaq)
ISIN US0197701065
Capitalisation 459M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

44 13
33 10
37 4
11
 
Dernier brevet 2025 - Methods of manufacturing allogen...
Premier brevet 2015 - Egfrviii specific chimeric antig...
Dernière marque 2024 - ITCAR
Première marque 2018 - ALLOGENE THERAPEUTICS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells. The present...
Invention Methods of manufacturing allogeneic car t cells. Described herein are improved media for culturi...
Invention Engineered cells. The present disclosure relates generally to nucleic acid constructs containing ...
Invention Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof. The present dis...
Invention Modified caspase-9 polypeptides and methods of use thereof. Provided herein are modified caspase...
Invention Methods of detection for engineered cells. Provided herein are approaches to detect the expressio...
Invention Constitutively active chimeric cytokine receptors. Provided herein are constitutively active chi...
Invention Inhibitory chimeric antigen receptors. The invention relates to an inhibitory chimeric antigen r...
P/S Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors; ...
2023 Invention Rituximab-resistant chimeric antigen receptors and uses thereof. Provided herein are polynucleot...
Invention Cd70 anti-idiotype antibodies. Provided herein are anti-idiotype antibodies that specifically re...
Invention Cd70 anti-idiotype antibodies
Invention Cd70 anti-idiotype antibodies. Provided herein are anti-idiotype antibodies that specifically rec...
Invention Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof. Provided ...
Invention Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof. Provided h...
Invention Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells. The present ...
Invention Mab-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells. A po...
Invention B-cell maturation antigen (bcma) anti-idiotypic antibodies. Provided herein are anti-idiotype an...
Invention B-cell maturation antigen (bcma) anti-idiotypic antibodies. Provided herein are anti-idiotype ant...
Invention Method for inhibiting adventitious viral infection. The instant disclosure relates to methods fo...
Invention In vitro method for inhibiting hhv-6 infection
Invention In vitro method for inhibiting hhv-6 infection. The instant disclosure relates to methods for pre...
Invention Chimeric cytokine receptors bearing a pd-1 ectodomain. Provided herein are PD-1 chimeric cytokin...
Invention Engineered cells with reduced gene expression to mitigate immune cell recognition. Provided here...
Invention Engineered cells with reduced gene expression to mitigate immune cell recognition. e.g.e.g.e.g., ...
Invention Engineered cells with reduced gene expression to mitigate immune cell recognition
Invention Anti-talen antibodies and uses thereof. The present disclosure provides, among other things, ant...
Invention Methods for detecting genomic abnormalities in cells. The instant disclosure relates to methods f...
P/S Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors;...
Invention Methods for donor cell analysis. Provided herein are methods, kits and reagents for analyzing th...
Invention Methods for donor cell analysis
Invention Methods for donor cell analysis. Provided herein are methods, kits and reagents for analyzing the...
Invention Dll3 targeting chimeric antigen receptors and binding agents. Provided herein are DLL3 binding a...
Invention Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signal...
Invention Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
P/S Printed publications, namely, pamphlets and brochures about research, detection, diagnosis, and m...
P/S Printed publications, namely, pamphlets and brochures about research, detection, diagnosis, and ...
2022 P/S Promoting public awareness about cancer; promoting public awareness about chimeric antigen recept...
Invention Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence...
Invention Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and...
Invention Formulations and processes for car t cell drug products. Provided herein are formulations and dru...
Invention Methods for transducing immune cells. Provided herein are improved methods for transducing immun...
Invention Knockdown or knockout of one or more of tap2, nlrc5, b2m, trac, rfx5, rfxap and rfxank to mitigat...
Invention Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigat...
Invention Knockdown or knockout of one or more of tap2, nlrc5, β2m, trac, rfx5, rfxap and rfxank to mitigat...
Invention Methods for transducing immune cells. Provided herein are improved methods for transducing immune...
2021 Invention Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma...
2019 P/S Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumours;...
2018 P/S Providing medical information to patients and medical professionals in the form of reports in the...